Adalimumab Biosimilar Market Size, Share And Global Trend By Product (Exemptia, Adalirel, Cipleumab, Others), By Distribution channel (Hospitals pharmacies, Retail pharmacies, Others), And Regional Forecast, 2024-2032
KEY MARKET INSIGHTS
A biosimilar is a type of biologic equivalent to that of pre-approved biologics. Adalimumab was the first fully human monoclonal antibody approved by the U.S. Food and Drug Administration in December 2002. Adalimumab is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and many other diseases. In September 2017, AbbVie Inc. lost patent of Humira, which led other manufacturers to introduce biosimilars of adalimumab in the market. Exemptia is the world’s first biosimilar of adalimumab, launched by Cadila Healthcare in December 2014.
The global adalimumab biosimilars market is expected to grow at a rapid pace during the forecast period, owing to the increasing incidence of arthritis among the global population and increase in the number of skin disorders leading to rise in demand for adalimumab. Additionally, the introduction of new biosimilars will lead to the decline in prices of the drugs in the global market, subsequently leading to high demand in the market. This is projected to fuel the growth of the global adalimumab biosimilars market during the forecast period.
To gain extensive insights into the market, Request for Customization
The factor that is expected to inhibit the growth of the market is the high sensitivity towards temperature, lack of efficacy and safety, high manufacturing cost compared to generic drugs.
Key Players Covered
Some of the major companies that are present in the global adalimumab biosimilar market are Alfred E. Tiefenbacher, Amgen Inc., Boehringer Ingelheim International GmbH, Glenmark Pharmaceuticals Ltd, Zydus Cadila, Torrent Pharmaceuticals Ltd., Reliance Life Sciences., Emcure Pharmaceuticals Ltd, Cipla Inc., Hetero. and others.
SEGMENTATION
SEGMENTATION | DETAILS |
By Product | · Exemptia · Adalirel · Cipleumab · Others |
By Distribution channel | · Hospitals pharmacies · Retail pharmacies · Others |
By Geography | · North America (USA and Canada) · Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) · Latin America (Brazil, Mexico and Rest of Latin America) · Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa) |
At present, the Exemptia is anticipated to account for the largest market share being the first biosimilar of adalimumab to be approved.
Key Insights
Pipeline analysis
Introduction of new products/approvals (by major players)
Key strategies by market players
Prevalence of arthritis and skin diseases (key regions/ countries).
Regional Analysis
The global adalimumab biosimilar market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America is anticipated to account for the largest share of the global adalimumab biosimilars market in 2018, owing to the increasing prevalence of rheumatoid arthritis combined with the rise in the geriatric population. Europe is expected to grow at a faster rate owing to a rise in the approvals of the new biosimilars, rise in aging population, high investment in the research and manufacturing of the new adalimumab biosimilars. As of 2018, five new adalimumab biosimilars have been approved in Europe, including AMGEVITA. These new biosimilars are expected to drive the growth of the global adalimumab biosimilars market in the forecast period. The increased focus to develop generic and biosimilar products in the emerging nations of Asia Pacific is estimated to fuel in the global adalimumab biosimilars market in these regions.
Key Industry Developments
- In October 2018, Samsung Bioepis launched IMRALDITM a biosimilar to adalimumab with joint venture between Samsung BioLogics and Biogen.
- In November 2018, Food and Drug Administration approved the Hyrimoz adalimumab biosimilar developed by Novartis AG.
- In October 2018, Amgen Inc., launched AMGEVITA a biosimilar of adalimumab.
- In August, 2017, Boehringer Ingelheim International GmbH received approval for the Cyltezo, a biosimilar of adalimumab.
- Ongoing
- 2023
- 2019-2022
-
Get in Touch with Us
-
US +1 833 909 2966 ( Toll Free )
-
